Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
4.125
-0.035 (-0.84%)
Nov 28, 2025, 4:00 PM EST - Market closed
Adverum Biotechnologies Stock Forecast
Stock Price Forecast
The 5 analysts that cover Adverum Biotechnologies stock have a consensus rating of "Buy" and an average price target of $11.6, which forecasts a 181.21% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $33.
Price Target: $11.6 (+181.21%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Adverum Biotechnologies stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $30 → $5 | Strong Buy → Hold | Downgrades | $30 → $5 | +21.21% | Nov 17, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | -3.03% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +627.27% | Sep 23, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +700.00% | Aug 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +190.91% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
12.91M
from 1.00M
Increased by 1,191.10%
Revenue Next Year
230.27K
from 12.91M
Decreased by -98.22%
EPS This Year
-5.98
from -6.62
EPS Next Year
-2.81
from -5.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 78.8M | 948,150 | ||||
| Avg | 12.9M | 230,265 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7,775.0% | -92.7% | ||||
| Avg | 1,191.1% | -98.2% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.72 | -0.56 | ||||
| Avg | -5.98 | -2.81 | ||||
| Low | -8.58 | -7.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.